<DOC>
	<DOCNO>NCT01313767</DOCNO>
	<brief_summary>This study randomize , double blind , multi-center , active drug control , phase III clinical trial compare efficacy safety MEDITOXIN® versus BOTOX® treatment post stroke upper limb ( wrist , finger , thumb ) spasticity Approximately 196 subject ( 1:1 group ratio ) enrol . Subjects receive single treatment intramuscular Investigational product 360U . The subject observe every 4 week 12 week post injection . Outcome measure include Modified Ashworth Scale ( MAS ) , Disability Assessment Scale ( DAS ) , Global Assessment Scale ( patient caregiver/investigator ) Carer burden scale . The primary efficacy endpoint change baseline week 4 wrist flexor muscle tone measure Modified Ashworth Scale . Safety parameter also measure include adverse event , vital sign clinical laboratory test ( haematology , serum chemistry urinanalysis ) .</brief_summary>
	<brief_title>MEDITOXIN® Versus BOTOX® Treatment Post-stroke Spasticity Upper Limb Spasticity</brief_title>
	<detailed_description>Each complete subject attend 4~5 clinic visit . The maximum study duration 15 week . Only one upper limb ( eligible inclusion/exclusion criterion ) inject evaluate study . Maximun injection dose 360U .</detailed_description>
	<mesh_term>Muscle Spasticity</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>1 . Male female patient ≥ 20 year 2 . ≥ 6 week since last stroke 3 . ≥ 2 point focal spasticity wrist flexor ≥ 1 point least one elbow flexor finger flexor measure MAS ( 0 4 ) 4 . Targeted one functional disability item ( i.e. , hygiene , dress , pain , cosmesis ) rating 2 great DAS ( 0 3 ) 5 . Informed consent obtain . 1 . Neuromuscular disorder LambertEaton syndrome , myasthenia gravis , amyotrophic lateral sclerosis 2 . History ( within 6 month screen visit ) plan ( study period ) treatment phenol alcohol injection surgery target limb 3 . History ( within 6 month screen visit ) plan ( study period ) treatment tendon lengthen target limb 4 . Fixed joint/muscle contracture 5 . Severe atrophy 6 . Concurrent treatment intrathecal baclofen 7 . History ( within 3 month screen visit ) Planned ( study period ) treatment Botulinum Toxin 8 . Known allergy sensitivity study medication component 9 . Concurrent plan Muscle relaxant and/or benzodiazepine medication If patient take medication stable one month screen treatment change plan study , participation allow . 10 . Current Physical , occupational , Splinting therapy If therapy regimen permit stable one month screening ; treatment change plan study . 11 . Patient participate clinical trial screen 12 . Females pregnant , breatfeeding , plan pregnancy study period , female childbearing potential , use reliable mean centraception . 13 . Patients eligible study discretion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>spasticity</keyword>
	<keyword>upperlimb</keyword>
	<keyword>Botulinum toxin</keyword>
</DOC>